Non-small-cell lung cancer (NSCLC) is the leading cause of cancer-related death worldwide, with ~40–50% of patients diagnosed with non-metastatic disease (stages IA–IIIC). The treatment landscape is evolving rapidly as immunotherapies and targeted therapy are introduced in the non-metastatic setting, creating a need to assess patient outcomes prior to their introduction. This real-world study using Swedish National Lung Cancer Registry data examined outcomes (overall survival (OS) and time to next treatment or death (TTNTD)) and treatment patterns for adults diagnosed with non-metastatic NSCLC. Baseline characteristics and OS from diagnosis were described for all patients; OS, treatment patterns, and TTNTD from treatment start were described for the treatment subgroup (patients diagnosed from 2014 onwards), stratified by disease stage and initial treatment. OS and TTNTD were described using the Kaplan–Meier estimator. The overall population (2008–2019) included 17,433 patients; the treatment subgroup included 5147 patients. Median OS (interquartile range) overall ranged from 83.3 (31.6–165.3) months (stage I patients) to 10.4 (4.3–24.2) months (stage IIIB patients). Among the treatment subgroup, median OS and TTNTD were longest among patients receiving surgery versus other anticancer treatments. These findings provide a baseline upon which to evaluate the epidemiology of non-metastatic NSCLC as newer treatments are introduced.
非小细胞肺癌是全球癌症相关死亡的主要原因，约40%-50%的患者在确诊时处于非转移性疾病阶段（IA–IIIC期）。随着免疫疗法和靶向治疗在非转移性肺癌领域的应用，治疗格局正在快速演变，这促使我们需要评估这些新疗法引入前的患者结局。本研究基于瑞典国家肺癌登记处的真实世界数据，分析了诊断为非转移性非小细胞肺癌成年患者的临床结局（总生存期及至下次治疗或死亡时间）与治疗模式。研究描述了全体患者的基线特征及自诊断起的总生存期；针对治疗亚组（2014年及之后确诊的患者），按疾病分期和初始治疗方案分层，描述了自治疗开始的总生存期、治疗模式及至下次治疗或死亡时间。总生存期与至下次治疗或死亡时间采用Kaplan-Meier估计法进行分析。总体人群（2008–2019年）共纳入17,433例患者；治疗亚组包含5,147例患者。全体患者中位总生存期（四分位距）从83.3个月（31.6–165.3）（I期患者）至10.4个月（4.3–24.2）（IIIB期患者）不等。在治疗亚组中，接受手术治疗的患者相较于其他抗癌治疗方案，其中位总生存期与至下次治疗或死亡时间均更长。这些研究结果为评估新型疗法引入后非转移性非小细胞肺癌的流行病学特征提供了基准参照。
肿瘤(癌症)患者之家